Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

769.88 +4.20 (+0.55%)
Official Closing Price Updated: 7:00 PM EDT, Jun 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
99 100 Next >
Verge Genomics Announces Milestones in Collaboration with Lilly to Discover and Develop Novel Treatments for ALS
From Verge Genomics
Via GlobeNewswire
Top Research Reports For Eli Lilly, PepsiCo & Morgan Stanley
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Co., PepsiCo, Inc., and Morgan Stanley. 
Via Talk Markets
What To Do After The Worst Week For Healthcare Stocks Since March 2020?
The market was quiet today but we should still expect some gains through year -end albeit a bit choppy. 
Via Talk Markets
Eli Lilly Stock Eyes Worst Month Since February 2009: Is It Time To Buy The Dip?
Eli Lilly & Co. shares plunge 12.5% this month, worst since 2009, due to disappointing earnings and lowered guidance. The future remains uncertain. 
Via Benzinga
Eli Lilly's Investigational Drug Cuts Sticky Cholesterol Levels By Almost 86%
Eli Lilly's muvalaplin Phase 2 trial showed significant Lp(a) reduction, meeting primary and secondary endpoints with favorable safety data. 
Via Benzinga
Eli Lilly Unusual Options Activity
Via Benzinga
Eli Lilly Unusual Options Activity For November 13
Via Benzinga
Jim Cramer: Coinbase Is A 'Winner,' Suggests Buying This 'Hated' Big Pharma Stock
Jim Cramer recommends buying hated stock Eli Lilly, while also praising Coinbase and IES Holdings. Marvell and Apple are also solid bets. 
Via Benzinga
The Smartest Megacap Growth ETF to Buy With $500 Right Now
Via The Motley Fool
Topics ETFs
Eli Lilly's Zepbound/Mounjaro Shows Cardiovascular Benefits In Patients With Obesity-Related Heart Failure
Eli Lilly's Phase 3 SUMMIT trial results show tirzepatide's potential to reduce heart failure risk and improve symptoms in obese adults with HFpEF. 
Via Benzinga
3 Growth Stocks You Can Buy Right Now Without Any Hesitation
Via The Motley Fool
If You Bought 1 Share of Eli Lilly in 1984, Here's How Many Shares You Would Own Now
Via The Motley Fool
Goldman Sachs Economist: Weight-Loss Drugs Could Be Key To US Economic Growth
A Goldman Sachs economist has suggested that the US economy could experience accelerated growth with increased use of GLP-1 weight-loss drugs like Ozempic. 
Via Benzinga
Topics Economy
Exposures Economy
Prediction: 3 Stocks That'll Be Worth More Than Tesla 10 Years From Now
These stocks have realistic paths to grow larger than Tesla. 
Via The Motley Fool
Not-So-Big Pharma
Thanks to the change in the Health and Human Services Department, 'big pharma' stocks are one of the very few sectors in equity-land that are seemingly unhappy about the forthcoming administration. 
Via Talk Markets
Prediction: Acquisitions Will Skyrocket Under The Trump Administration. Here's 1 Pharmaceutical Company I Have My Eyes On.
Mergers and acquisitions could make a comeback with Trump headed back to Washington. 
Via The Motley Fool
Topics Government
Exposures Political
AskSlim Market Week - Friday, Nov. 15
An analysis and commentary on the financial markets. 
Via Talk Markets
Powell Speaks The Truth - Market Does Not Like It, Consternation About Kennedy, Gaetz, And Hegseth
To gain an edge, this is what you need to know today. 
Via Benzinga
Mounjaro-Maker Eli Lilly Files Lawsuit Against US Agency Over Drug Rebate Program
Eli Lilly proposed a plan to ensure 340B entities pay no more than the ceiling price by providing them with cash directly on a weekly basis. 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Should You Forget Eli Lilly and Buy This Magnificent Biotech Stock Instead?
Via The Motley Fool
99% Of Mounjaro/Zepbound Patients Remained Diabetes-Free Even At 3 Years, Eli Lilly's Detailed Phase 3 Data Shows
Eli Lilly's Phase 3 study shows tirzepatide significantly cuts type 2 diabetes risk and supports 22.9% average weight loss in adults over three years. 
Via Benzinga
Why Are These 3 Vanguard ETFs Underperforming the S&P 500 Since Election Day?
Stocks in these "safe" sectors are selling off as investors gravitate toward growth. 
Via The Motley Fool
Topics ETFs Stocks
Exposures US Equities
2 Top Growth Stocks to Buy on the Dip
Their recent issues are nothing to fret over for investors focused on the long game. 
Via The Motley Fool
3 Ultra-Safe Dividend Stocks That Have Been Paying Dividends for More Than 100 Years
These are income stocks you can buy and hold forever. 
Via The Motley Fool
Amgen Defends Its Investigational Monthly Weight Loss Injection After Analyst Cites MariTide's Impact on Bone Density
Amgen addresses safety concerns for its weight loss drug MariTide after new data suggests a potential 4% reduction in bone density at the highest dose. 
Via Benzinga
Did Viking Therapeutics Just Say "Checkmate" To Eli Lilly?
Viking Therapeutics just revealed a new plan that could make waves in the weight loss industry. 
Via The Motley Fool
Humanitarian Organization Criticizes Eli Lilly, Novo Nordisk And Sanofi Of Having 'Double Standards' For High Insulin Price
MSF calls for insulin manufacturers to provide $1 injection pens globally, emphasizing current high prices and limited access. Novo Nordisk's production shift raises concerns as diabetes cases rise,... 
Via Benzinga
2 S&P 500 Dividend Stocks That Could Soar 30% or More, According to a Pair of Wall Street Analysts
If Wall Street's right, investors will get a lot more than just rising dividend payments from this pair. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Jim Cramer Says Eli Lilly's 'Pathetic' Stock Performance Could Get A Breather If Amgen Has Hidden Bone Risk Data After 7% Stock Drop
Amgen Inc.'s stock dropped over 7% on Tuesday following revelations about bone density loss in early trials of its experimental obesity drug MariTide, while CNBC's Jim Cramer suggested the news could... 
Via Benzinga
Tradepulse Power Inflow Alert: Eli Lilly & Company Moves Up Over 13 Points After Signal
Via Benzinga
< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.